This touches on the negotiation that MAPS is involved in with the FDA about the credentials required in the room. On the one hand those who have experience with MDMA, Psilocybin and others recognize that the therapeutic alliance does not require doctorate level training, such expertise should be in the building and involved in screening but not needed in every treatment session, MAPS is arguing.
This last point seems motivated and doesnt take into account that the measure essentially creates a working group to develop the program with many of the details left to be decided.
I wonder if similar campaigns could bring in state psychiatric groups into discussion and collaboration sooner in the process or if the Oregon group did so and the OPPA wasn't up for it.